Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Onkologia w Praktyce Klinicznej - Edukacja
MENU
Na skróty Ahead of print Zdeponuj artykuł Nagroda imienia Profesora Krzysztofa Krzemienieckiego Zalecenia postępowania diagnostyczno-terapeutycznego

Tom 9, Nr 3 (2023)
Wytyczne / stanowisko ekspertów
Opublikowany online: 2022-12-12
Dodaj do koszyka: 95,00 PLN
Pobierz cytowanie

Postępowanie diagnostyczno-terapeutyczne u chorych na mięsaki tkanek miękkich u dorosłych — zalecenia ekspertów

Piotr Rutkowski1, Hanna Koseła-Paterczyk1, Katarzyna Kozak1, Iwona Ługowska1, Jacek Fijuth2, Arkadiusz Jeziorski2, Janusz Ryś3, Mateusz Spałek1, Aneta Borkowska1, Michał Wągrodzki1, Tomasz Świtaj1, Piotr Fonrobert4, Urszula Grzesiakowska1, Zbigniew I. Nowecki1, Mariusz Bidziński1, Andrzej Tysarowski1, Hanna Tchórzewska-Korba1, Marcin Zdzienicki1
Onkol Prakt Klin Edu 2023;9(3):149-180.
Afiliacje
  1. Narodowy Instytut Onkologii — Instytut im. Marii Skłodowskiej-Curie — Państwowy Instytut Badawczy w Warszawie
  2. Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii w Łodzi, Uniwersytet Medyczny w Łodzi
  3. Narodowy Instytut Onkologii Centrum Onkologii — Instytut im. Marii Skłodowskiej-Curie — Państwowy Instytut Badawczy, Oddział w Krakowie
  4. Stowarzyszenie Pomocy Chorym na GIST

dostęp płatny

Tom 9, Nr 3 (2023)
WYTYCZNE POSTĘPOWANIA DIAGNOSTYCZNO-TERAPEUTYCZNEGO
Opublikowany online: 2022-12-12

Streszczenie

Brak

Streszczenie

Brak

Pełny tekst:

Dodaj do koszyka: 95,00 PLN
Pobierz cytowanie

Słowa kluczowe

mięsaki; tkanki miękkie; GIST; diagnostyka; terapia

Informacje o artykule
Tytuł

Postępowanie diagnostyczno-terapeutyczne u chorych na mięsaki tkanek miękkich u dorosłych — zalecenia ekspertów

Czasopismo

Onkologia w Praktyce Klinicznej - Edukacja

Numer

Tom 9, Nr 3 (2023)

Typ artykułu

Wytyczne / stanowisko ekspertów

Strony

149-180

Opublikowany online

2022-12-12

Wyświetlenia strony

991

Wyświetlenia/pobrania artykułu

361

Rekord bibliograficzny

Onkol Prakt Klin Edu 2023;9(3):149-180.

Słowa kluczowe

mięsaki
tkanki miękkie
GIST
diagnostyka
terapia

Autorzy

Piotr Rutkowski
Hanna Koseła-Paterczyk
Katarzyna Kozak
Iwona Ługowska
Jacek Fijuth
Arkadiusz Jeziorski
Janusz Ryś
Mateusz Spałek
Aneta Borkowska
Michał Wągrodzki
Tomasz Świtaj
Piotr Fonrobert
Urszula Grzesiakowska
Zbigniew I. Nowecki
Mariusz Bidziński
Andrzej Tysarowski
Hanna Tchórzewska-Korba
Marcin Zdzienicki

Referencje (118)
  1. Walewski J, Dziurda D, Bidziński M, et al. Consensus on methods of development of clinical practice guidelines in oncology under the auspices of Maria Sklodowska-Curie National Research Institute of Oncology and the Agency for Health Technology Assessment and Tariff System. Nowotwory. Journal of Oncology. 2022; 72(1): 44–50.
    CrossRef
  2. Blay JY, Soibinet P, Penel N, et al. Improved survival using specialized multidisciplinary board in sarcoma patients. Ann Oncol. 2017; 28(11): 2852–2859.
    CrossRefPubMed
  3. Andritsch E, Beishon M, Bielack S, et al. ECCO Essential Requirements for Quality Cancer Care: Soft Tissue Sarcoma in Adults and Bone Sarcoma. A critical review. Crit Rev Oncol Hematol. 2017; 110: 94–105.
    CrossRefPubMed
  4. Gronchi A, Miah AB, Dei Tos AP, et al. ESMO Guidelines Committee, EURACAN and GENTURIS. Electronic address: clinicalguidelines@esmo.org. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(11): 1348–1365.
    CrossRefPubMed
  5. Rutkowski P. (ed.). Mięsaki tkanek miękkich. Via Medica, Gdańsk 2015.
  6. Wojciechowska U, Didkowska J, Michałek I, Olasek P, Ciuba A. Nowotwory złośliwe w Polsce 2018. Cancer in Poland in 2018. Krajowy Rejestr Nowotworów, Warszawa 2020.
  7. Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie — Państwowy Instytut Badawczy. http://onkologia.org.pl/r.
  8. Fletcher CDM, Bridge JA, Hogendoorn PC. Classification of tumours of soft tissue and bone. IARC, Lyon 2013.
  9. WHO Classification of Tumours Editorial Board. Tissue and Bone Tumours. WHO Classification of Tumours, 5th Edition, Volume 3. World Health Organization, Lyon 2020.
  10. Dei Tos AP, Agaimy A, Bovee J, et al (2021). Soft Tissue Sarcoma Histopathology Reporting Guide Resection Specimens. International Collaboration on Cancer Reporting; Sydney, Australia. http://www.iccr-cancer.org/datasets/published-datasets/soft-tissue-bone.
  11. Rutkowski P, Prochorec-Sobieszek M, Wągrodzki M, et al. Diagnostyka z wykorzystaniem sekwencjonowania następnej generacji (NGS) w mięsakach — rekomendacje. Onkol Prakt Klin Edu. 2020; 6(1): 1–8.
  12. Patomorfologia: standardy i przykłady dobrej praktyki oraz praktyki oraz elementy diagnostyki różnicowej. Wytyczne dla zakładów/pracowni patomorfologii: 406–419.
  13. NCCN Clinical Practice in Oncology. Soft Tissue Sarcoma. V.1.2021.
  14. Lasota J. MOLECULAR GENETICS OF SOFT TISSUE TUMORS. Modern Soft Tissue Pathology. 2010: 127–180.
    CrossRef
  15. Soft tissue sarcoma. In: Edge SB, Byrd DR, Compton CC. ed. AJCC Cancer Staging Manual. Springer, New York 2010: 291–296.
  16. Folpe AL, Nielsen GP. Bone and soft tissue pathology. II ed. Elsevier 2022.
  17. Amin MB, Edge S, Greene FA. Cancer Staging Manual, 8th edition. Springer International Publishing, Cham 2017.
  18. Callegaro D, Miceli R, Bonvalot S, et al. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. Lancet Oncol. 2016; 17(5): 671–680.
    CrossRefPubMed
  19. Gronchi A, Miceli R, Shurell E, et al. Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets. J Clin Oncol. 2013; 31(13): 1649–1655.
    CrossRefPubMed
  20. Bonvalot S, Miceli R, Berselli M, et al. Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control. Ann Surg Oncol. 2010; 17(6): 1507–1514.
    CrossRefPubMed
  21. Gronchi A, Miceli R, Colombo C, et al. Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. Ann Oncol. 2012; 23(4): 1067–1073.
    CrossRefPubMed
  22. Bonvalot S, Raut CP, Pollock RE, et al. Technical considerations in surgery for retroperitoneal sarcomas: position paper from E-Surge, a master class in sarcoma surgery, and EORTC-STBSG. Ann Surg Oncol. 2012; 19(9): 2981–2991.
    CrossRefPubMed
  23. Trans-Atlantic RPS Working Group. Management of primary retroperitoneal sarcoma (RPS) in the adult: a consensus approach from the Trans-Atlantic RPS Working Group. Ann Surg Oncol. 2015; 22(1): 256–263.
    CrossRefPubMed
  24. Gronchi A, Strauss DC, Miceli R, et al. Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group. Ann Surg. 2016; 263(5): 1002–1009.
    CrossRefPubMed
  25. Alektiar K. Soft-Tissue Sarcoma. Clinical Radiation Oncology. 2016: 1345–1372.e4.
    CrossRef
  26. Rossi CR, Vecchiato A, Mastrangelo G, et al. Adherence to treatment guidelines for primary sarcomas affects patient survival: a side study of the European CONnective TIssue CAncer NETwork (CONTICANET). Ann Oncol. 2013; 24(6): 1685–1691.
    CrossRefPubMed
  27. Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982; 196(3): 305–315.
    CrossRefPubMed
  28. Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998; 16(1): 197–203.
    CrossRefPubMed
  29. Pisters PW, Harrison LB, Leung DH, et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol. 1996; 14(3): 859–868.
    CrossRefPubMed
  30. O'Sullivan B, Davis A, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002; 359(9325): 2235–2241.
    CrossRefPubMed
  31. Salerno KE, Alektiar KM, Baldini EH, et al. Radiation Therapy for Treatment of Soft Tissue Sarcoma in Adults: Executive Summary of an ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2021; 11(5): 339–351.
    CrossRefPubMed
  32. O'Sullivan B, Griffin AM, Dickie CI, et al. Phase 2 study of preoperative image-guided intensity-modulated radiation therapy to reduce wound and combined modality morbidities in lower extremity soft tissue sarcoma. Cancer. 2013; 119(10): 1878–1884.
    CrossRefPubMed
  33. https://www.nrgoncology.org/Portals/0/Scientific%20Program/CIRO/Atlases/RTOGsarcoma.pdf.
  34. Spałek MJ, Koseła-Paterczyk H, Borkowska A, et al. Combined Preoperative Hypofractionated Radiotherapy With Doxorubicin-Ifosfamide Chemotherapy in Marginally Resectable Soft Tissue Sarcomas: Results of a Phase 2 Clinical Trial. Int J Radiat Oncol Biol Phys. 2021; 110(4): 1053–1063.
    CrossRefPubMed
  35. Spałek MJ, Rutkowski P. Coronavirus Disease (COVID-19) Outbreak: Hypofractionated Radiotherapy in Soft Tissue Sarcomas as a Valuable Option in the Environment of Limited Medical Resources and Demands for Increased Protection of Patients. Front Oncol. 2020; 10: 993.
    CrossRefPubMed
  36. Kalbasi A, Kamrava M, Chu FI, et al. A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma. Clin Cancer Res. 2020; 26(8): 1829–1836.
    CrossRefPubMed
  37. Koseła-Paterczyk H, Szacht M, Morysiński T, et al. Preoperative hypofractionated radiotherapy in the treatment of localized soft tissue sarcomas. Eur J Surg Oncol. 2014; 40(12): 1641–1647.
    CrossRefPubMed
  38. Spałek MJ, Borkowska AM, Telejko M, et al. The Feasibility Study of Hypofractionated Radiotherapy with Regional Hyperthermia in Soft Tissue Sarcomas. Cancers (Basel). 2021; 13(6).
    CrossRefPubMed
  39. Koseła-Paterczyk H, Szacht M, Morysiński T, et al. Preoperative hypofractionated radiotherapy in the treatment of localized soft tissue sarcomas. Eur J Surg Oncol. 2014; 40(12): 1641–1647.
    CrossRefPubMed
  40. Koseła-Paterczyk H, Spałek M, Borkowska A, et al. Hypofractionated Radiotherapy in Locally Advanced Myxoid Liposarcomas of Extremities or Trunk Wall: Results of a Single-Arm Prospective Clinical Trial. J Clin Med. 2020; 9(8).
    CrossRefPubMed
  41. Lansu J, Bovée JV, Braam P, et al. Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: A Nonrandomized Controlled Trial. JAMA Oncol. 2021; 7(1): e205865.
    CrossRefPubMed
  42. Lansu J, Bovée JV, Braam P, et al. Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: A Nonrandomized Controlled Trial. JAMA Oncol. 2021; 7(1): e205865.
    CrossRefPubMed
  43. Koseła-Paterczyk H, Spałek M, Borkowska A, et al. Hypofractionated Radiotherapy in Locally Advanced Myxoid Liposarcomas of Extremities or Trunk Wall: Results of a Single-Arm Prospective Clinical Trial. J Clin Med. 2020; 9(8).
    CrossRefPubMed
  44. Bonvalot S, Rutkowski P, Thariat J, et al. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial. Lancet Oncol. 2019; 20(8): 1148–1159.
    CrossRef
  45. Spałek MJ, Borkowska AM, Telejko M, et al. The Feasibility Study of Hypofractionated Radiotherapy with Regional Hyperthermia in Soft Tissue Sarcomas. Cancers (Basel). 2021; 13(6).
    CrossRefPubMed
  46. Bonvalot S, Gronchi A, Le Péchoux C, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020; 21(10): 1366–1377.
    CrossRefPubMed
  47. Sobiborowicz A, Spałek MJ, Czarnecka AM, et al. Definitive Radiotherapy in the Management of Non-Resectable or Residual Retroperitoneal Sarcomas: Institutional Cohort Analysis and Systematic Review. Cancer Control. 2021; 28: 1073274820983028.
    CrossRefPubMed
  48. Kelly KJ, Yoon SS, Kuk D, et al. Comparison of Perioperative Radiation Therapy and Surgery Versus Surgery Alone in 204 Patients With Primary Retroperitoneal Sarcoma: A Retrospective 2-Institution Study. Ann Surg. 2015; 262(1): 156–162.
    CrossRefPubMed
  49. Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008; 113(3): 573–581.
    CrossRefPubMed
  50. Gronchi A, Frustaci S, Mercuri M, et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol. 2012; 30(8): 850–856.
    CrossRefPubMed
  51. Pasquali S, Pizzamiglio S, Touati N, et al. EORTC – Soft Tissue and Bone Sarcoma Group. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. Eur J Cancer. 2019; 109: 51–60.
    CrossRefPubMed
  52. Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017; 18(6): 812–822.
    CrossRef
  53. Gronchi A, Palmerini E, Quagliuolo V, et al. Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. J Clin Oncol. 2020; 38(19): 2178–2186.
    CrossRefPubMed
  54. Pasquali S, Pizzamiglio S, Touati N, et al. EORTC – Soft Tissue and Bone Sarcoma Group. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. Eur J Cancer. 2019; 109: 51–60.
    CrossRefPubMed
  55. Issels R, Lindner L, Verweij J, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2010; 11(6): 561–570.
    CrossRef
  56. Trabulsi NH, Patakfalvi L, Nassif MO, et al. Hyperthermic isolated limb perfusion for extremity soft tissue sarcomas: systematic review of clinical efficacy and quality assessment of reported trials. J Surg Oncol. 2012; 106(8): 921–928.
    CrossRefPubMed
  57. Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993; 11(7): 1276–1285.
    CrossRefPubMed
  58. Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014; 15(4): 415–423.
    CrossRef
  59. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007; 25(19): 2755–2763.
    CrossRefPubMed
  60. Demetri G, Mehren Mv, Jones R, et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016; 34(8): 786–793.
    CrossRef
  61. Graaf Wv, Blay JY, Chawla S, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012; 379(9829): 1879–1886.
    CrossRef
  62. D'Ambrosio L, Touati N, Blay JY, et al. European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Cancer. 2020; 126(11): 2637–2647.
    CrossRefPubMed
  63. Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014; 15(4): 415–423.
    CrossRef
  64. Rutkowski P, Van Glabbeke M, Rankin CJ, et al. European Organisation for Research and Treatment of Cancer Soft Tissue/Bone Sarcoma Group, Southwest Oncology Group. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010; 28(10): 1772–1779.
    CrossRefPubMed
  65. Schöffski P, Sufliarsky J, Gelderblom H, et al. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. Lancet Respir Med. 2018; 6(6): 431–441.
    CrossRef
  66. Waguespack SG, Drilon A, Lin JJ, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018; 378(8): 731–739.
    CrossRefPubMed
  67. Drilon A, Chiu CH, Fan Y, et al. trial investigators, trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020; 21(2): 271–282.
    CrossRefPubMed
  68. Coyne GO, Sharon E, Moore N, et al. Phase II study of atezolizumab in patients with alveolar soft part sarcoma. Presented at: 2018 CTOS Annual Meeting, Paper 021. Rome, 14–17 November 2018.
  69. Stacchiotti S, Provenzano S, Dagrada G, et al. Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database. Ann Surg Oncol. 2016; 23(9): 2735–2744.
    CrossRefPubMed
  70. Blay JY, Leahy MG, Nguyen BB, et al. Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. Eur J Cancer. 2014; 50(6): 1137–1147.
    CrossRefPubMed
  71. Cesne ALe, Blay JY, Cupissol D, et al. Results of a prospective randomized phase III T-SAR trial comparing trabectedin vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS). Annals of Oncology. 2016; 27: vi483.
    CrossRef
  72. Cesne A, Blay JY, Domont J, et al. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. Lancet Oncol. 2015; 16(3): 312–319.
    CrossRef
  73. Schöffski P, Chawla S, Maki R, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016; 387(10028): 1629–1637.
    CrossRef
  74. Tap W, Jones R, Tine BV, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016; 388(10043): 488–497.
    CrossRef
  75. Gounder M, Stacchiotti S, Schöffski P, et al. Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950). J Clin Oncol. 2017; 35(15_suppl): 11058–11058.
    CrossRef
  76. https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf.
  77. https://clinicaltrials.gov/ct2/show/NCT04498767.
  78. Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020; 21(1): e18–e28.
    CrossRefPubMed
  79. Spałek MJ, Czarnecka AM, Rutkowski P. The Management of Radiation-Induced Sarcomas: A Cohort Analysis from a Sarcoma Tertiary Center. J Clin Med. 2021; 10(4).
    CrossRefPubMed
  80. Bjerkehagen B, Smeland S, Walberg L, et al. Radiation-induced sarcoma: 25-year experience from the Norwegian Radium Hospital. Acta Oncol. 2008; 47(8): 1475–1482.
    CrossRefPubMed
  81. Callesen LB, Safwat A, Rose HK, et al. Radiation-Induced Sarcoma: A Retrospective Population-Based Study Over 34 Years in a Single Institution. Clin Oncol (R Coll Radiol). 2021; 33(5): e232–e238.
    CrossRefPubMed
  82. Bjerkehagen B, Småstuen MC, Hall KS, et al. Why do patients with radiation-induced sarcomas have a poor sarcoma-related survival? Br J Cancer. 2012; 106(2): 297–306.
    CrossRefPubMed
  83. Roeder F, Morillo V, Saleh-Ebrahimi L, et al. Intraoperative radiation therapy (IORT) for soft tissue sarcoma - ESTRO IORT Task Force/ACROP recommendations. Radiother Oncol. 2020; 150: 293–302.
    CrossRefPubMed
  84. Voutsadakis IA, Zaman K, Leyvraz S. Breast sarcomas: current and future perspectives. Breast. 2011; 20(3): 199–204.
    CrossRefPubMed
  85. Bousquet G, Confavreux C, Magné N, et al. Outcome and prognostic factors in breast sarcoma: a multicenter study from the rare cancer network. Radiother Oncol. 2007; 85(3): 355–361.
    CrossRefPubMed
  86. Rutkowski P, Śpiewankiewicz B, Koseła H, et al. Sarcoma of the uterus: diagnostic and therapeutic recommendations. Current Gynecologic Oncology. 2013; 11(1): 24–32.
    CrossRef
  87. McMeekin DS. Sarcoma of the uterus. In: DiSaia P, Creasman W. ed. Clinical gynecologic oncology. Eight edition. Elsevier 2013: 175–188.
  88. Reed NS, Mangioni C, Malmström H, et al. European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008; 44(6): 808–818.
    CrossRefPubMed
  89. Desmoid Tumor Working Group. The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer. 2020; 127: 96–107.
    CrossRefPubMed
  90. Gronchi A, Colombo C, Le Péchoux C, et al. ISG and FSG. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group. Ann Oncol. 2014; 25(3): 578–583.
    CrossRefPubMed
  91. Kasper B, Baumgarten C, Bonvalot S, et al. Desmoid Working Group. Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients' and professionals' expertise - a sarcoma patients EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative. Eur J Cancer. 2015; 51(2): 127–136.
    CrossRefPubMed
  92. Gounder MM, Mahoney MR, Van Tine BA, et al. Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med. 2018; 379(25): 2417–2428.
    CrossRefPubMed
  93. Toulmonde M, Pulido M, Ray-Coquard I, et al. Pazopanib or methotrexate–vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol. 2019; 20(9): 1263–1272.
    CrossRef
  94. Toulmonde M, Pulido M, Ray-Coquard I, et al. Pazopanib or methotrexate–vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. Lancet Oncol. 2019; 20(9): 1263–1272.
    CrossRef
  95. Kasper B, Gruenwald V, Reichardt P, et al. Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG). Eur J Cancer. 2017; 76: 60–67.
    CrossRefPubMed
  96. Rutkowski P, Lugowska I. Follow-up in soft tissue sarcomas. Memo. 2014; 7(2): 92–96.
    CrossRefPubMed
  97. Miettinen M, Lasota J. Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001; 438(1): 1–12.
    CrossRefPubMed
  98. Casali PG, Blay JY, Abecassis N, et al. ESMO Guidelines Committee, EURACAN and GENTURIS. Electronic address: clinicalguidelines@esmo.org. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022; 33(1): 20–33.
    CrossRefPubMed
  99. Rutkowski P, Szumera-Ciećkiewicz A. Gastrointestinal stromal tumours (GIST) — 2018. Oncol Clin Pract. 2019; 14(6): 399–407.
    CrossRef
  100. Ohtani H, Maeda K, Noda E, et al. Meta-analysis of laparoscopic and open surgery for gastric gastrointestinal stromal tumor . Anticancer Res. 2013; 33(11): 5031–5041.
    PubMed
  101. Rutkowski P, Gronchi A, Hohenberger P, et al. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol. 2013; 20(9): 2937–2943.
    CrossRefPubMed
  102. Rutkowski P, Wozniak A, Dębiec-Rychter M, et al. Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection. Cancer. 2011; 117(21): 4916–4924.
    CrossRefPubMed
  103. Rutkowski P, Nowecki ZI, Michej W, et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol. 2007; 14(7): 2018–2027.
    CrossRefPubMed
  104. Joensuu H, Vehtari A, Riihimäki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2012; 13(3): 265–274.
    CrossRefPubMed
  105. Joensuu H, Eriksson M, Sundby Hall K, et al. Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. J Clin Oncol. 2016; 34(3): 244–250.
    CrossRefPubMed
  106. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008; 26(4): 620–625.
    CrossRefPubMed
  107. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347(7): 472–480.
    CrossRefPubMed
  108. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol. 2010; 28(7): 1247–1253.
    CrossRefPubMed
  109. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003; 21(23): 4342–4349.
    CrossRefPubMed
  110. Demetri G, Oosterom Av, Garrett C, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006; 368(9544): 1329–1338.
    CrossRefPubMed
  111. Reichardt P, Kang YK, Rutkowski P, et al. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer. 2015; 121(9): 1405–1413.
    CrossRefPubMed
  112. George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer. 2009; 45(11): 1959–1968.
    CrossRefPubMed
  113. Reichardt P, Kang YK, Rutkowski P, et al. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer. 2015; 121(9): 1405–1413.
    CrossRefPubMed
  114. Demetri G, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013; 381(9863): 295–302.
    CrossRefPubMed
  115. Montemurro M, Gelderblom H, Bitz U, et al. Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. Eur J Cancer. 2013; 49(5): 1027–1031.
    CrossRefPubMed
  116. Jones RL, Serrano C, von Mehren M, et al. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer. 2021; 145: 132–142.
    CrossRefPubMed
  117. Blay JY, Serrano C, Heinrich M, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020; 21(7): 923–934.
    CrossRefPubMed
  118. Bauer S, Rutkowski P, Hohenberger P, et al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study). Eur J Surg Oncol. 2014; 40(4): 412–419.
    CrossRefPubMed

Regulamin

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

 

Wydawcą serwisu jest  VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl